LENZ
LENZ Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.50
−0.14%0
Insider buys (3m)
3
Insider sells (3m)
-$9.1M
Net value (3m)
-34.0%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Nov 3, 2026 | Chevallard Daniel R. · officer: Chief Financial Officer | A-Award | 652,063 | $3.05 |
| Nov 2, 2026 | RA CAPITAL MANAGEMENT, L.P. · 10 percent owner | Sale | 2,159,516 | $3.36 |
| Nov 2, 2026 | RA CAPITAL MANAGEMENT, L.P. · 10 percent owner | Sale | 451,998 | $3.36 |
| Nov 2, 2026 | RA CAPITAL MANAGEMENT, L.P. · 10 percent owner | Sale | 107,170 | $3.36 |
| Jun 15, 2026 | Drapkin Kimberlee C · director | A-Award | 22,100 | $6.63 |
| Jun 15, 2026 | George Jeffrey P. · director | A-Award | 22,100 | $6.63 |
| Jun 15, 2026 | RA CAPITAL MANAGEMENT, L.P. · director, 10 percent owner: | A-Award | 22,100 | $6.63 |
| Jun 15, 2026 | Scheiner Zachary · director | A-Award | 22,100 | $6.63 |
| Jun 15, 2026 | Guerard Frederic · director | A-Award | 22,100 | $6.63 |
| Jun 15, 2026 | Thunen Shelley B · director | A-Award | 22,100 | $6.63 |
| Jun 15, 2026 | MCCOLLUM JAMES W · director | A-Award | 22,100 | $6.63 |
| Mar 30, 2026 | Schimmelpennink Evert B. · director, officer: President, CEO and Secretary | Purchase | 28,089 | $8.95 |
| Mar 30, 2026 | Chevallard Daniel R. · officer: Chief Financial Officer | Purchase | 7,500 | $8.57 |
| Mar 30, 2026 | George Jeffrey P. · director | Purchase | 5,592 | $8.92 |
| Jan 6, 2026 | Olsson Shawn · officer: Chief Commercial Officer | A-Award | 14,000 | $0.00 |
| Jan 6, 2026 | Odrich Marc · officer: Chief Medical Officer | A-Award | 84,200 | $16 |
| Jan 6, 2026 | Odrich Marc · officer: Chief Medical Officer | A-Award | 14,000 | $0.00 |
| Jan 6, 2026 | Chevallard Daniel R. · officer: Chief Financial Officer | A-Award | 84,200 | $16 |
| Jan 6, 2026 | Chevallard Daniel R. · officer: Chief Financial Officer | A-Award | 14,000 | $0.00 |
| Jan 6, 2026 | Schimmelpennink Evert B. · director, officer: President, CEO and Secretary | A-Award | 358,100 | $16 |
| Jan 6, 2026 | Olsson Shawn · officer: Chief Commercial Officer | A-Award | 84,200 | $16 |
| Nov 19, 2025 | Olsson Shawn · officer: Chief Commercial Officer | M-Exempt | 10,000 | $2.08 |
| Nov 19, 2025 | Olsson Shawn · officer: Chief Commercial Officer | Sale | 5,788 | $26 |
| Nov 19, 2025 | Olsson Shawn · officer: Chief Commercial Officer | Sale | 4,212 | $26 |
| Nov 10, 2025 | MCCOLLUM JAMES W · director | Purchase | 10,500 | $23 |
| Nov 7, 2025 | Chevallard Daniel R. · officer: Chief Financial Officer | Purchase | 20 | $23 |
| Nov 7, 2025 | Chevallard Daniel R. · officer: Chief Financial Officer | Purchase | 2,178 | $23 |
| Oct 2, 2025 | Versant Venture Capital VI, L.P. · 10 percent owner | Sale | 49,701 | $45 |
| Oct 2, 2025 | Versant Venture Capital VI, L.P. · 10 percent owner | Sale | 83,066 | $46 |
| Oct 2, 2025 | Versant Venture Capital VI, L.P. · 10 percent owner | Sale | 177 | $47 |
Institutional positioning
13F filings over the trailing two quarters
New 60Increased 112Reduced 65Sold out 43
| Filer | Action | Shares | Filed |
|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | Unchanged | 4,178,823 | May 15, 2026 |
| RA CAPITAL MANAGEMENT, L.P. | Unchanged | 4,178,823 | Aug 14, 2026 |
| Alpha Wave Global, LP | Unchanged | 3,612,211 | Aug 13, 2026 |
| ALPHA WAVE GLOBAL, LP | Unchanged | 3,612,211 | May 14, 2026 |
| FMR LLC | Reduced | 3,597,784 | May 15, 2026 |
| FMR LLC | Reduced | 3,558,905 | Aug 13, 2026 |
| Versant Venture Management, LLC | Unchanged | 2,656,888 | Aug 12, 2026 |
| VERSANT VENTURE MANAGEMENT, LLC | Unchanged | 2,656,888 | May 5, 2026 |
| BlackRock, Inc. | Increased | 2,292,121 | Aug 7, 2026 |
| BLACKROCK, INC. | Increased | 1,976,823 | May 13, 2026 |
| Squarepoint Ops LLC | Increased | 1,747,096 | Aug 14, 2026 |
| Aberdeen Group plc | Increased | 1,547,883 | Jul 31, 2026 |
| MILLENNIUM MANAGEMENT LLC | Increased | 1,508,478 | Aug 14, 2026 |
| SQUAREPOINT OPS LLC | Increased | 1,506,499 | May 15, 2026 |
| FRANKLIN RESOURCES INC | Increased | 1,100,148 | May 13, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Nov 3, 2026